Do interleukin-17 and interleukin-23 inhibitors alter the coagulation parameters in psoriasis patients?: A retrospective study
Authors:
- 11 September 2024
- journal article
- research article
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 316 (8) , 1-6
Abstract
Psoriasis is a chronic inflammatory skin condition associated with systemic inflammation and a higher risk of cardiovascular comorbidities. This study retrospectively evaluates coagulation parameters in psoriasis vulgaris patients treated with IL-17 inhibitors (secukinumab, ixekizumab) and IL-23 inhibitors (risankizumab, guselkumab), compared to those untreated systemically. The study reviewed records from 177 patients treated between January 2019 and March 2023. Patients were grouped into control (n = 77), secukinumab (n = 36), ixekizumab (n = 19), guselkumab (n = 24), and risankizumab (n = 21). Coagulation parameters, including PT, aPTT, PLT, MPV, INR, fibrinogen, D-dimer, and B12 levels, were analyzed. The primary endpoint was the comparison of coagulation parameters between groups. Significant differences were found in PT, with secukinumab-treated patients showing a significantly shorter PT compared to controls (p = 0.002). No significant differences were observed in other coagulation parameters across the groups. The study highlights a potential effect of secukinumab on coagulation pathways, possibly related to IL-17’s role in inflammation and endothelial function. Despite current literature suggest a risk of cerebrovascular events with risankizumab, this study did not show any significant changes in coagulation parameters with risankizumab, indicating no hypercoagulability risk associated with this IL-23 inhibitor. Our findings suggest IL-17 and IL-23 inhibitors are generally safe concerning coagulation parameters, but regular monitoring may be warranted for patients on secukinumab due to its effect on PT. Further long-term studies are needed to fully understand the cardiovascular risks associated with these therapies.Keywords
This publication has 21 references indexed in Scilit:
- Thrombosis in Psoriasis: Cutaneous Cytokine Production as a Potential Driving Force of Haemostatic Dysregulation and Subsequent Cardiovascular RiskFrontiers in Immunology, 2021
- Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamicsJournal of Dermatological Treatment, 2020
- National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling studyBMJ, 2020
- Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled TrialsJournal of Immunology Research, 2019
- Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and ConsequencesFrontiers in Immunology, 2018
- The relationship between duration of psoriasis, vascular inflammation, and cardiovascular eventsJournal of the American Academy of Dermatology, 2017
- Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trialsBritish Journal of Dermatology, 2016
- Is enhanced platelet activation the missing link leading to increased cardiovascular risk in psoriasis?Clinica Chimica Acta, 2015
- Hypercoagulability detected by whole blood thromboelastometry (ROTEM®) and impedance aggregometry (MULTIPLATE®) in obese patientsThrombosis Research, 2015
- Inflammation and Hypercoagulable State in Adult Psoriatic MenActa Dermato-Venereologica, 2008